New 'Reference Regimen' in Metastatic Pancreatic Cancer?

Liposomal irinotecan plus chemo in the new NALIRIFOX regimen significantly improved overall survival compared with standard therapy in metastatic pancreatic ductal adenocarcinoma.
Medscape Medical News

source https://www.medscape.com/viewarticle/987317?src=rss